Premium
Economic evaluation of the development of a phage therapy product for the control of Salmonella in poultry
Author(s) -
TorresAcosta Mario A.,
Clavijo Viviana,
Vaglio Christopher,
GonzálezBarrios Andrés F.,
VivesFlórez Martha J.,
RitoPalomares Marco
Publication year - 2019
Publication title -
biotechnology progress
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 129
eISSN - 1520-6033
pISSN - 8756-7938
DOI - 10.1002/btpr.2852
Subject(s) - salmonella , production (economics) , bioprocess , poultry farming , microbiology and biotechnology , salmonella enteritidis , biomass (ecology) , bioreactor , environmental science , pulp and paper industry , biology , veterinary medicine , engineering , bacteria , medicine , economics , agronomy , macroeconomics , paleontology , genetics , botany
Poultry products are one of the major transmission media of Salmonella enteritidis to humans. A promising alternative to reduce the load of Salmonella in poultry are bacteriophages. Elsewhere, a mixture of six bacteriophages has been used successfully, but large‐scale production would be necessary to supply potential poultry market and costs analyses have not been calculated yet. For this, a powerful tool to predict production costs is bioprocess modeling coupled with economic analyses. This work aims to model the scaled‐up production of a six bacteriophages mixture based on a laboratory/pilot‐scale production using Biosolve Process. For the model construction, a combination of experimental and reported data was applied, in which different production alternatives and the range of 1–100% of the Colombian poultry market (at broiler's farm and slaughterhouse) were analyzed. Results indicate that the best cost‐effective process configuration/scale is to use one bioreactor (156 L) for the six bacteriophages, then a 0.45 μm filtration for removal of biomass, and a 0.22 μm filtration for sterility; this to supply the 35% of the market size for broiler farms (equivalent to 210 million chickens). This configuration gives a production cost per chicken of US$ 0.02. Additionally, a sensitivity analysis and a theoretical contrast for understanding the impact that titer and recovery have on production scale determined that titer affects the most the cost and requires optimization. The present works serves as a first, and required, approach for the development of phage therapy products that are alternatives to present‐day pathogens control strategies.